Publications

Found 2 results
Filters: Author is F.F.O. Rodrigues  [Clear All Filters]
2010
A. L. Oliveira, Rodrigues, F. F. O., Santos, R. E., Aoki, T., Rocha, M. N., Longui, C. A., and Melo, M. B., GSTT1, GSTM1, and GSTP1 polymorphisms and chemotherapy response in locally advanced breast cancer, vol. 9, pp. 1045-1053, 2010.
Adler V, Yin Z, Fuchs SY, Benezra M, et al. (1999). Regulation of JNK signaling by GSTp. EMBO J. 18: 1321-1334. http://dx.doi.org/10.1093/emboj/18.5.1321 PMid:10064598 PMCid:1171222   Allan JM, Wild CP, Rollinson S, Willett EV, et al. (2001). Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc. Natl. Acad. Sci. U. S. A. 98: 11592-11597. http://dx.doi.org/10.1073/pnas.191211198 PMid:11553769 PMCid:58774   Alpert LC, Schecter RL, Berry DA, Melnychuk D, et al. (1997). Relation of glutathione S-transferase alpha and mu isoforms to response to therapy in human breast cancer. Clin. Cancer Res. 3: 661-667. PMid:9815734   Ambrosone CB, Sweeney C, Coles BF, Thompson PA, et al. (2001). Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer. Cancer Res. 61: 7130-7135. PMid:11585745   Arrick BA and Nathan CF (1984). Glutathione metabolism as a determinant of therapeutic efficacy: a review. Cancer Res. 44: 4224-4232. PMid:6380705   Burg D and Mulder GJ (2002). Glutathione conjugates and their synthetic derivatives as inhibitors of glutathione-dependent enzymes involved in cancer and drug resistance. Drug Metab. Rev. 34: 821-863. http://dx.doi.org/10.1081/DMR-120015695 PMid:12487151   Cho SG, Lee YH, Park HS, Ryoo K, et al. (2001). Glutathione S-transferase mu modulates the stress-activated signals by suppressing apoptosis signal-regulating kinase 1. J. Biol. Chem. 276: 12749-12755. http://dx.doi.org/10.1074/jbc.M005561200 PMid:11278289   Daly AK (2003). Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam. Clin. Pharmacol. 17: 27-41. http://dx.doi.org/10.1046/j.1472-8206.2003.00119.x PMid:12588628   Dang DT, Chen F, Kohli M, Rago C, et al. (2005). Glutathione S-transferase pi1 promotes tumorigenicity in HCT116 human colon cancer cells. Cancer Res. 65: 9485-9494. http://dx.doi.org/10.1158/0008-5472.CAN-05-1930 PMid:16230413   Dirven HA, van Ommen B and van Bladeren PJ (1994). Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione. Cancer Res. 54: 6215-6220. PMid:7954469   Hamada S, Kamada M, Furumoto H, Hirao T, et al. (1994). Expression of glutathione S-transferase-pi in human ovarian cancer as an indicator of resistance to chemotherapy. Gynecol. Oncol. 52: 313-319. http://dx.doi.org/10.1006/gyno.1994.1055 PMid:8157188   Hayes JD and Pulford DJ (1995). The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit. Rev. Biochem. Mol. Biol. 30: 445-600. http://dx.doi.org/10.3109/10409239509083491 PMid:8770536   Howells RE, Holland T, Dhar KK, Redman CW, et al. (2001). Glutathione S-transferase GSTM1 and GSTT1 genotypes in ovarian cancer: association with p53 expression and survival. Int. J. Gynecol. Cancer 11: 107-112. http://dx.doi.org/10.1046/j.1525-1438.2001.011002107.x PMid:11328408   Huang J, Tan PH, Thiyagarajan J and Bay BH (2003). Prognostic significance of glutathione S-transferase-pi in invasive breast cancer. Mod. Pathol. 16: 558-565. http://dx.doi.org/10.1097/01.MP.0000071842.83169.5A PMid:12808061   Khedhaier A, Remadi S, Corbex M, Ahmed SB, et al. (2003). Glutathione S-transferases (GSTT1 and GSTM1) gene deletions in Tunisians: susceptibility and prognostic implications in breast carcinoma. Br. J. Cancer 89: 1502-1507. http://dx.doi.org/10.1038/sj.bjc.6601292 PMid:14562023 PMCid:2394332   L'Ecuyer T, Allebban Z, Thomas R and Vander Heide R (2004). Glutathione S-transferase overexpression protects against anthracycline-induced H9C2 cell death. Am. J. Physiol. Heart Circ. Physiol. 286: H2057-2064. http://dx.doi.org/10.1152/ajpheart.00778.2003 PMid:14726301   Leonessa F and Clarke R (2003). ATP binding cassette transporters and drug resistance in breast cancer. Endocr. Relat. Cancer 10: 43-73. http://dx.doi.org/10.1677/erc.0.0100043 PMid:12653670   Leyland-Jones BR, Townsend AJ, Tu CP, Cowan KH, et al. (1991). Antineoplastic drug sensitivity of human MCF-7 breast cancer cells stably transfected with a human alpha class glutathione S-transferase gene. Cancer Res. 51: 587-594. PMid:1985777   Lizard-Nacol S, Coudert B, Colosetti P, Riedinger JM, et al. (1999). Glutathione S-transferase M1 null genotype: lack of association with tumour characteristics and survival in advanced breast cancer. Breast Cancer Res. 1: 81-87. http://dx.doi.org/10.1186/bcr17 PMid:11056682 PMCid:13914   McIlwain CC, Townsend DM and Tew KD (2006). Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene 25: 1639-1648. http://dx.doi.org/10.1038/sj.onc.1209373 PMid:16550164   Morrow CS, Smitherman PK, Diah SK, Schneider E, et al. (1998). Coordinated action of glutathione S-transferases (GSTs) and multidrug resistance protein 1 (MRP1) in antineoplastic drug detoxification. Mechanism of GST A1-1- and MRP1-associated resistance to chlorambucil in MCF7 breast carcinoma cells. J. Biol. Chem. 273: 20114-20120. http://dx.doi.org/10.1074/jbc.273.32.20114 PMid:9685354   Moscow JA, Townsend AJ and Cowan KH (1989). Elevation of pi class glutathione S-transferase activity in human breast cancer cells by transfection of the GSTpi gene and its effect on sensitivity to toxins. Mol. Pharmacol. 36: 22-28. PMid:2747627   Naoe T, Tagawa Y, Kiyoi H, Kodera Y, et al. (2002). Prognostic significance of the null genotype of glutathione S-transferase-T1 in patients with acute myeloid leukemia: increased early death after chemotherapy. Leukemia 16: 203-208. http://dx.doi.org/10.1038/sj.leu.2402361 PMid:11840286   O'Brien ML and Tew KD (1996). Glutathione and related enzymes in multidrug resistance. Eur. J. Cancer 32: 967-978. http://dx.doi.org/10.1016/0959-8049(96)00051-2   O'Brien M, Kruh GD and Tew KD (2000). The influence of coordinate overexpression of glutathione phase II detoxification gene products on drug resistance. J. Pharmacol. Exp. Ther. 294: 480-487. PMid:10900222   Pakunlu RI, Cook TJ and Minko T (2003). Simultaneous modulation of multidrug resistance and antiapoptotic cellular defense by MDR1 and BCL-2 targeted antisense oligonucleotides enhances the anticancer efficacy of doxorubicin. Pharm. Res. 20: 351-359. http://dx.doi.org/10.1023/A:1022687617318 PMid:12669953   Parkin DM, Bray F, Ferlay J and Pisani P (2005). Global cancer statistics, 2002. CA Cancer J. Clin. 55: 74-108. http://dx.doi.org/10.3322/canjclin.55.2.74 PMid:15761078   Paumi CM, Ledford BG, Smitherman PK, Townsend AJ, et al. (2001). Role of multidrug resistance protein 1 (MRP1) and glutathione S-transferase A1-1 in alkylating agent resistance. Kinetics of glutathione conjugate formation and efflux govern differential cellular sensitivity to chlorambucil versus melphalan toxicity. J. Biol. Chem. 276: 7952-7956. http://dx.doi.org/10.1074/jbc.M009400200 PMid:11115505   Riddick DS, Lee C, Ramji S, Chinje EC, et al. (2005). Cancer chemotherapy and drug metabolism. Drug Metab. Dispos. 33: 1083-1096. http://dx.doi.org/10.1124/dmd.105.004374 PMid:16049130   Rodrigues FF, Santos RE, Melo MB, Silva MA, et al. (2008). Correlation of polymorphism C3435T of the MDR-1 gene and the response of primary chemotherapy in women with locally advanced breast cancer. Genet. Mol. Res. 7: 177-183. http://dx.doi.org/10.4238/vol7-1gmr400 PMid:18393221   Russo A and Mitchell JB (1985). Potentiation and protection of doxorubicin cytotoxicity by cellular glutathione modulation. Cancer Treat. Rep. 69: 1293-1296. PMid:4092192   Schisselbauer JC, Silber R, Papadopoulos E, Abrams K, et al. (1990). Characterization of glutathione S-transferase expression in lymphocytes from chronic lymphocytic leukemia patients. Cancer Res. 50: 3562-3568. PMid:2340505   Shea TC, Claflin G, Comstock KE, Sanderson BJ, et al. (1990). Glutathione transferase activity and isoenzyme composition in primary human breast cancers. Cancer Res. 50: 6848-6853. PMid:2208151   Tew KD (1994). Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 54: 4313-4320. PMid:8044778   Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, et al. (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92: 205-216. http://dx.doi.org/10.1093/jnci/92.3.205 PMid:10655437   Townsend AJ and Cowan KH (1989). Glutathione S-transferases and antineoplastic drug resistance. Cancer Bull. 41: 31-36   Townsend D and Tew K (2003a). Cancer drugs, genetic variation and the glutathione-S-transferase gene family. Am. J. Pharmacogenomics 3: 157-172. http://dx.doi.org/10.2165/00129785-200303030-00002 PMid:12814324   Townsend DM and Tew KD (2003b). The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 22: 7369-7375. http://dx.doi.org/10.1038/sj.onc.1206940 PMid:14576844   Wilson MH, Grant PJ, Hardie LJ and Wild CP (2000). Glutathione S-transferase M1 null genotype is associated with a decreased risk of myocardial infarction. FASEB J. 14: 791-796. PMid:10744635   Yang G, Shu XO, Ruan ZX, Cai QY, et al. (2005). Genetic polymorphisms in glutathione-S-transferase genes (GSTM1, GSTT1, GSTP1) and survival after chemotherapy for invasive breast carcinoma. Cancer 103: 52-58. http://dx.doi.org/10.1002/cncr.20729 PMid:15565566